ClinicalTrials.gg

Program

LY4256984

A development code.

Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Eli Lilly.

Furthest: phase 1, since Jul 31, 20253 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly33 open or runningphase 1since Jul 31, 2025Jul 31, 2025Aug 2027phase 1 · NCT07100119

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2025First study: phase 1 study in Amyotrophic Lateral SclerosisFirst studyNCT07100119 · 36 planned · Belgium, Canada, Germany and more
  2. Apr 30, 20262 phase 1 studies in Amyotrophic Lateral SclerosisNCT07571200, NCT07571174

Ahead

  1. Aug 2027Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT07100119
  2. Jun 2029Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT07571200
  3. Jun 2029Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT07571174

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07571200Amyotrophic Lateral Sclerosis · Belgium, Canada, Germany and more1RecruitingJun 202932
NCT07571174Amyotrophic Lateral Sclerosis · Belgium, Canada, Germany and more1RecruitingJun 202932
NCT07100119Amyotrophic Lateral Sclerosis · Belgium, Canada, Germany and more1RecruitingAug 202736

How it is read

Names in the registry

  • “LY4256984”, 3 entries

Codes read as this program: LY4256984.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.